AIDS News and Research

RSS

Selzentry (maraviroc) becomes fully approved HIV antiretrovial

The U.S. Food and Drug Administration (FDA) has granted Selzentry (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals.

25 Nov 2008

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

AIDS advocates tell WHO: Stop harmful single-dose treatment for expectant mothers and infants

As World AIDS Day 2008 approaches, a coalition of hundreds of HIV/AIDS medical care providers and advocates, representing dozens of organizations, today sent a letter to Dr. Margaret Chan, Director General of the World Health Organization (WHO), urging an end to harmful single-dose HIV/AIDS treatment as a recommended treatment for expectant mothers and infants worldwide.

25 Nov 2008

A more rational and scientific approach to AIDS is needed, says expert

The Secretariat of the Joint United Nations Programme on HIV/AIDS (UNAIDS) has lost valuable ground by ignoring for years the contribution of long-term concurrent relationships to Africa's AIDS epidemic, claims an expert ahead of World AIDS Day on bmj.com.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Study shows true economic cost of living with multiple sclerosis

A study of people living with the devastating effects of multiple sclerosis (MS) has shown the true economic cost of living with the incurable, life-long condition.

24 Nov 2008

Prion switching in response to environmental stress

If you have had a hard day at work, you may change your eating habits, perhaps favoring comfort food, but you don't suddenly develop the ability to eat the plate and cutlery.

24 Nov 2008

Viral Genetics completes acquisition of V-Clip Pharmaceuticals

Viral Genetics, Inc. has announced it has completed its acquisition of V-Clip Pharmaceuticals, Inc. ("V-Clip").

19 Nov 2008

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.

19 Nov 2008

Why are so many infectious diseases jumping from animals to humans?

Why do we have so little capacity to predict epidemics, or avoid them? Some answers, and possible solutions, can be found in the first trench-to-bench guide to wild primate infectious diseases, published Nov. 17 in the Yearbook of Physical Anthropology.

18 Nov 2008

Risk of non-AIDS cancer higher for individuals infected with HIV

The risk of non-AIDS cancer is higher for individuals infected with HIV than for the general population, according to a meta-analysis presented here at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.

18 Nov 2008

International health research boosted by NIH grant to create bioethics master's degrees at Indiana and Moi Universities

A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research.

18 Nov 2008

New and improved scientific method to forecast the demand for key anti-malarial treatments

Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.

17 Nov 2008

New research reveals key steps in HIV's assault on the brain

Scientists have unraveled in unprecedented detail the cascade of events that go wrong in brain cells affected by HIV, a virus whose assault on the nervous system continues unabated despite antiviral medications that can keep the virus at bay for years in the rest of the body.

16 Nov 2008

Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy

A previously unknown regulatory step during human immunodeficiency (HIV) replication provides a potentially valuable new target for HIV/AIDS therapy, report researchers at the Salk Institute for Biological Studies and the University of Wisconsin, Madison.

16 Nov 2008

New clue for cellular damage in Huntington's disease

"Huntington's disease presents an ideal vantage point to study neurodegenerative disease, because we know the misfolded protein that's responsible," says Martin Duennwald, formerly a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist.

16 Nov 2008

Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Genetic Immunity, a US/Hungarian clinical-stage company focused on development of nanomedicines for targeted immune amplification, today announced it has treated the first subject in a Phase II clinical study to evaluate DermaVir Patch.

13 Nov 2008

Analyses of Merck's HIV vaccine 'Step' study

Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online in two papers in The Lancet.

12 Nov 2008

Impact of the global financial and economic crisis on health

We face a severe financial crisis of unprecedented dimensions in a world that has never before been so closely connected and interdependent. The consequences are global. The situation is volatile. The current financial crisis is rapidly becoming an economic crisis and threatens to become a social crisis in many countries.

12 Nov 2008

XDR-TB declining in the U.S.

A new report suggests that the number of cases of extensively drug-resistant tuberculosis (XDR-TB) in the U.S. has declined in the past fifteen years, but new cases continue to be reported, according to the study published in the November 12 issue of JAMA.

11 Nov 2008